×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
THTX – theratechnologies inc. - common shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
THTX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
10/17
02:05 pm
thtx
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV [Financial Post (Toronto, Ontario, Canada)]
10/17
02:00 pm
thtx
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
Low
Report
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
10/17
07:35 am
thtx
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance [Financial Post (Toronto, Ontario, Canada)]
10/17
07:30 am
thtx
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
Low
Report
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
10/10
10:49 am
thtx
Theratechnologies Inc. (THTX) Q3 2024 Earnings Call Transcript [Seeking Alpha]
Low
Report
Theratechnologies Inc. (THTX) Q3 2024 Earnings Call Transcript [Seeking Alpha]
10/9
07:36 am
thtx
Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV [Financial Post (Toronto, Ontario, Canada)]
Medium
Report
Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV [Financial Post (Toronto, Ontario, Canada)]
10/9
07:30 am
thtx
Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV
Medium
Report
Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV
9/26
07:30 am
thtx
Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update
Low
Report
Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
04:56 pm
thtx
Form SCHEDULE 13G/A Theratechnologies Inc. Filed by: Nantahala Capital Management, LLC
Low
Report
Form SCHEDULE 13G/A Theratechnologies Inc. Filed by: Nantahala Capital Management, LLC
10/10
08:37 am
thtx
Form 6-K Theratechnologies Inc. For: Oct 10
Medium
Report
Form 6-K Theratechnologies Inc. For: Oct 10
10/10
08:32 am
thtx
Form 6-K Theratechnologies Inc. For: Oct 10
Medium
Report
Form 6-K Theratechnologies Inc. For: Oct 10
9/25
11:06 am
thtx
Form 6-K Theratechnologies Inc. For: Sep 25
Low
Report
Form 6-K Theratechnologies Inc. For: Sep 25
9/18
10:02 am
thtx
Form 6-K Theratechnologies Inc. For: Sep 18
Low
Report
Form 6-K Theratechnologies Inc. For: Sep 18
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/4
Theratechnologies Signs Agreements With Massachusetts General Hospital and Dr. Steven Grinspoon
19.1%
3/3 Theratechnologies Inc. (NASDAQ: THTX) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $95.50 price target on the stock. 17.7%
4/14 Theratechnologies Announces Financial Results for the First Quarter of 2020 11.8%
10/14 REMINDER - Tesamorelin Study Results on NAFLD Published in Lancet HIV 9.9%
4/16 Theratechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 6.8%
10/21 Theratechnologies Provides Details About R&D Day Webcast 4.7%
3/11 Visceral Fat is a Predictor of Liver Fibrosis and Fibrosis Progression in People Living With HIV 3.8%
3/13 Form 6-K Theratechnologies Inc. For: Mar 13 3.4%
1/10 Theratechnologies Inc. (NASDAQ: THTX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 3.4%
12/19 Form 6-K Theratechnologies Inc. For: Dec 19 2.6%
3/3 Theratechnologies Inc. (NASDAQ: THTX) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $95.50 price target on the stock. 17.7%
4/14 Theratechnologies Announces Financial Results for the First Quarter of 2020 11.8%
10/14 REMINDER - Tesamorelin Study Results on NAFLD Published in Lancet HIV 9.9%
4/16 Theratechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 6.8%
10/21 Theratechnologies Provides Details About R&D Day Webcast 4.7%
3/11 Visceral Fat is a Predictor of Liver Fibrosis and Fibrosis Progression in People Living With HIV 3.8%
3/13 Form 6-K Theratechnologies Inc. For: Mar 13 3.4%
1/10 Theratechnologies Inc. (NASDAQ: THTX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 3.4%
12/19 Form 6-K Theratechnologies Inc. For: Dec 19 2.6%
TOP News Decliners
11/15
Form F-10/A Theratechnologies Inc.
-12.3%
10/10 Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing -7.5%
4/15 Theratechnologies Inc. (THTX) Q1 2020 Earnings Call Transcript [The Motley Fool] -5.4%
12/2 Theratechnologies Inc. (NASDAQ: THTX) is now covered by analysts at Canaccord Genuity. They set a "buy" rating on the stock. -5.1%
11/22 Form EFFECT Theratechnologies Inc. -4.1%
3/31 Form 6-K Theratechnologies Inc. For: Mar 31 -3.6%
11/25 Theratechnologies Starts Commercialization of New EGRIFTA SV?? in the United States -2.6%
10/11 Form F-X Theratechnologies Inc. Filed by: Theratechnologies Inc. -2.0%
2/18 Theratechnologies to Announce Financial Results for Fourth Quarter and Fiscal Year 2019 -1.8%
3/10 Form 6-K Theratechnologies Inc. For: Mar 10 -1.7%
10/10 Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing -7.5%
4/15 Theratechnologies Inc. (THTX) Q1 2020 Earnings Call Transcript [The Motley Fool] -5.4%
12/2 Theratechnologies Inc. (NASDAQ: THTX) is now covered by analysts at Canaccord Genuity. They set a "buy" rating on the stock. -5.1%
11/22 Form EFFECT Theratechnologies Inc. -4.1%
3/31 Form 6-K Theratechnologies Inc. For: Mar 31 -3.6%
11/25 Theratechnologies Starts Commercialization of New EGRIFTA SV?? in the United States -2.6%
10/11 Form F-X Theratechnologies Inc. Filed by: Theratechnologies Inc. -2.0%
2/18 Theratechnologies to Announce Financial Results for Fourth Quarter and Fiscal Year 2019 -1.8%
3/10 Form 6-K Theratechnologies Inc. For: Mar 10 -1.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: